Ortho Clinical Diagnostics Holdings

Ortho Clinical Diagnostics is a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions. Because Every Test is a LifeTM, we never stop innovating to offer streamlined, sustainable laboratory solutions that deliver fast, accurate, reliable test results that support exceptional patient care. As a trusted partner of hospitals, hospital networks, blood banks, and labs around the world, we proudly serve the clinical laboratory and transfusion medicine communities with customized solutions that enhance clinical outcomes, improve lab performance, overcome staffing challenges and better manage costs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ortho-Clinical Diagnostics is a manufacturer of medical equipment. They provide hospitals, hospital networks, clinical laboratories, and blood banks. They specialize in in vitro diagnostics and are dedicated to improving them through laboratory testing and blood-typing solutions.

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc (“Ortho”), one of the world's larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022.

Quidel and Ortho Announce Expected Closing of Ortho Transaction

RARITAN, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX) (“Ortho” or the “Company”), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation (NASDAQ: QDEL) (“Quidel”) pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto (the “BCA”). The closing of the transactions contemplated by the BCA is subject to sanction of the combination by the High Court of Justice of England and Wales and satisfaction of other closing conditions and is expected to occur on May 27, 2022.

Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction

Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Bryan Brokmeier - Vice President, Investor Relations Chris Smith - Chairman and Chief Executive Officer Joseph Busky - Chief Financial Officer Operator Welcome to the Ortho Clinical Diagnostics First Quarter 2022 Earnings Conference Call and Webcast. At this time, all participants lines are in a listen-only mode.

Ortho Clinical Diagnostics Holdings PLC (OCDX) CEO Chris Smith on Q1 2022 Results - Earnings Call Transcript

Ortho Clinical (OCDX) delivered earnings and revenue surprises of 15% and 1.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ortho Clinical Diagnostics (OCDX) Q1 Earnings Top Estimates

Ortho Clinical (OCDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Ortho Clinical (OCDX) Could Beat Earnings Estimates Again

Ortho Clinical (OCDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ortho Clinical Diagnostics (OCDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Gold Award Recognizes Antibody Test Gold Award Recognizes Antibody Test

Ortho Clinical Diagnostics Recognized with Fifth Prestigious Edison Award for Highly Accurate COVID-19 Solution

RARITAN, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2022 ended April 3, 2022, after the market close on Wednesday, May 4, 2022.

Ortho Clinical Diagnostics to Report First Quarter 2022 Results on May 4, 2022

Doximity

OCDX vs. DOCS: Which Stock Is the Better Value Option?

Ortho Clinical (OCDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Ortho Clinical (OCDX) Upgraded to Strong Buy: Here's What You Should Know

Progyny

OCDX vs. PGNY: Which Stock Is the Better Value Option?

OCDX vs. PGNY: Which Stock Should Value Investors Buy Now?

The mean of analysts' price targets for Ortho Clinical (OCDX) points to a 57.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 58% Upside in Ortho Clinical (OCDX): Here's What You Should Know

QuidelOrtho Corp

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Ortho Clinical Diagnostics Holdings plc (NasdaqGS: OCDX) to Quidel Corporation (NasdaqGS: QDEL). Under the terms of the proposed transaction, shareholders of Ortho will receive only $7.14 in cash and 0.1055 shares of common stock in the combined company for each share of Ortho that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whe

ORTHO CLINICAL INVESTOR ALERT - Kuznicki Law PLLC Investigates Adequacy of Price and Process in Proposed Sale of Ortho Clinical Diagnostics Holdings plc - OCDX

Ortho Care® Service and Support recognized for dedication to solving customer challenges with unique solutions that deliver exceptional patient care Ortho Care® Service and Support recognized for dedication to solving customer challenges with unique solutions that deliver exceptional patient care

Ortho Clinical Diagnostics Wins Bronze Stevie® Award for Customer Service and Support

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ortho Clinical Diagnostics Holdings plc (NasdaqGS: OCDX) to Quidel Corporation (NasdaqGS: QDEL). Under the terms of the proposed transaction, shareholders of Ortho will receive only $7.14 in cash and 0.1055 shares of common stock in the combined company for each share of Ortho that they own. KSF is seeking to

ORTHO CLINICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ortho Clinical Diagnostics Holdings plc - OCDX

Ortho Clinical (OCDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will Ortho Clinical (OCDX) Gain on Rising Earnings Estimates?

The consensus price target hints at a 54.3% upside potential for Ortho Clinical (OCDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 54% Upside in Ortho Clinical (OCDX): Can the Stock Really Move This High?

Civitas Resources

Clearwater Paper

Designer Brands

WESCO

CIVI, CLW, OCDX, WCC, and DBI have been added to the Zacks Rank #1 (Strong Buy) List on February 18, 2022.

New Strong Buy Stocks for February 18th

CIVI, DBI, and OCDX made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 18, 2022

Best Value Stocks to Buy for February 18th

Ortho Clinical Diagnostics Holdings PLC (OCDX) CEO Christopher Smith on Q4 2021 Results - Earnings Call Transcript

Ortho Clinical (OCDX) delivered earnings and revenue surprises of 20% and 0.39%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ortho Clinical Diagnostics (OCDX) Tops Q4 Earnings and Revenue Estimates

Strong Revenue Growth Drives Financial Results Strong Revenue Growth Drives Financial Results

Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2021 Results

RARITAN, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Further to the joint announcement by Ortho and Quidel Corporation (“Quidel”) on December 23, 2021 of the signing of a definitive business combination agreement, Ortho announces that, as a preliminary procedural step in the process of implementing the combination, Ortho has scheduled a hearing of the High Court of Justice of England and Wales (the “UK Court”) to seek the UK Court's consent and directions to convene a meeting of Ortho shareholders as part of the scheme of arrangement of Ortho proposed to be made pursuant to Part 26 of the Companies Act 2006 (the “UK Scheme”) for the purpose of implementing the business combination (the “UK Scheme Directions Hearing”).

Ortho Clinical Diagnostics Holdings Plc (“Ortho”): Notice of UK Court Scheme Directions Hearing

Expects 4Q Reported and Constant Currency Core Revenue Growth of ~4% Fiscal Year Reported and Constant Currency Core Revenue Growth of ~16% and ~15%, respectively

Ortho Clinical Diagnostics Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2021

RARITAN, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, with a virtual presentation scheduled for 9:00am ET.

News for Ortho Clinical Diagnostics Holdings Stock (OCDX)